TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1297878
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical trainings without coronary active agents
Study: 1297878
Drug: Physical exercises
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercises with antianginal drugs (first control group)
Study: 1297878
Drug: Therapeutical exercises,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutical exercises, graded walking, nitrates, beta-blockers, calcium antagonists (second control group)
Study: 6381170
Drug: Theocontin Continus
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theocontin Continus tablets
Study: 28646416
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (solifenacin 5 mg plus mirabegron 25 mg for the first 4 weeks/50 mg for the last 8 weeks)
Study: 2288826
Drug: Sulpiride (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (400 mg)
Study: 15084619
Drug: High-dose sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sequential chemotherapy and autografting
Study: 12404273
Drug: No estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: No estrogen replacement therapy (No ERT)
Study: 350590
Drug: β‐acetyl digoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐acetyl digoxin (D) 0.1, 0.2, 0.3, 0.4, 0.5 or 0.6 mg daily for 7 days
Study: 350590
Drug: digitoxin (Dt)
Normalized name: Digitoxin
DrugBank: Digitoxin (DB01396)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: digitoxin (Dt) 0.04, 0.08, 0.12, or 0.16 mg daily for 7 days
Study: 30592476
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (2 μg/kg)
Study: 23497981
Drug: Placebo (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intranasal water)
Study: 30676487
Drug: Single 900mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 900mg oral dose of delafloxacin
Study: 30676487
Drug: Single 250mg
Normalized name: docusate
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 250mg intramuscular ceftriaxone
Study: 25172875
Drug: Computerized insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computerized insulin infusion program (CIIP)
Study: 22775976
Drug: AZD1656 (7,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 (7, 20, 40 or 80 mg) twice daily for 8 days
Study: 22775976
Drug: AZD1656 (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 (15-45 mg) twice daily for 28 days
Study: 8506191
Drug: nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nisoldipine 10 mg twice a day for 8 weeks
Study: 8506191
Drug: nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 20 mg twice a day for 8 weeks
Study: 2965139
Drug: Oral procaterol
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral procaterol hydrochloride at 25 micrograms
Study: 27145977
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone (2 to 8 mg) delivered in low volumes (0.1 to 0.2 mL) using an Aptar Unit‐Dose device
Study: 27145977
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone (4 mg) delivered in a single device (0.1 mL)
Study: 24675370
Drug: IA injection
Normalized name: factor VIIa Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA injection of 30IU of BoNT A
Study: 22617279
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg per day of lactotripeptides for 3 months
Study: 22617279
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg per day of lactotripeptides for 3 months
Study: 9722212
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin solution (UW group)
Study: 9722212
Drug: Bretschneider's Histidine‐Tryptophan‐Ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretschneider's Histidine‐Tryptophan‐Ketoglutarate solution (HTK group)
Study: 8067218
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural bupivacaine/morphine for 48 h postoperatively plus oral piroxicam
Study: 8067218
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia followed by a conventional intramuscular opioid and acetaminophen regimen
Study: 31362882
Drug: Intravenous Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ketamine 0.5mg.kg‐1 (Group K‐IV)
Study: 31362882
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and Nebulized Ketamine Groups
Study: 28062595
Drug: 68Ga-PSMA-11 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-PSMA-11 PET/CT at 3 h after injection
Study: 28062595
Drug: 68Ga-PSMA-11 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-PSMA-11 PET/CT at 1 h after injection
Study: 28062595
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg) before late scans
Study: 28062595
Drug: Late scans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late scans (3 h after injection)
Study: 28062595
Drug: Early scans
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early scans (1 h after injection)
Study: 23896980
Drug: Sirukumab 1
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 1 mg/kg
Study: 23896980
Drug: Sirukumab 4
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 4 mg/kg
Study: 23896980
Drug: Sirukumab 10
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 10 mg/kg
Study: 28052588
Drug: Sirukumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab (all doses)
Study: 22321594
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (n=81)
Study: 22321594
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (n=25)
Study: 18927241
Drug: Vernakalant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Vernakalant (DB06217)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vernakalant hydrochloride injection (3 mg/kg initially via 10-minute intravenous infusion followed by a second 2 mg/kg 10-minute infusion if atrial fibrillation persisted)
Study: 18927241
Drug: Vernakalant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Vernakalant (DB06217)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vernakalant hydrochloride injection (1 or 2 infusions)
Study: 18927241
Drug: Vernakalant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Vernakalant (DB06217)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vernakalant hydrochloride injection
Study: 11206684
Drug: Sildenafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (5 to 200 mg)
Study: 9795316
Drug: ACLS medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACLS medications (epinephrine, atropine, bicarbonate, calcium, lidocaine)
Study: 30759221
Drug: Subcutaneous denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous denosumab 60 mg every 6 months for 3 years, then 7 years of open-label denosumab
Study: 30759221
Drug: Subcutaneous denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous denosumab 60 mg
Study: 28392436
Drug: PRX-106 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX-106 (all doses)
Study: 23263473
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (5.25 mg/kg)
Study: 21109557
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 25 mg subcutaneous injections twice weekly
Study: 10492661
Drug: Itraconazole pulse
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole pulse therapy (1 week 400 mg daily, 3 months)
Study: 10492661
Drug: Continuous terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous terbinafine dosing (250 mg daily, 3 months)
Study: 1725023
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 or 10 mg daily)
Study: 30908754
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Tranexamic Acid
Study: 21968126
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg daily
Study: 10326743
Drug: Pidotimod (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (400 mg oral bottle/day for 90 days)
Study: 7927099
Drug: Flupirtine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (100 mg, n = 35)
Study: 7927099
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg, n = 36)
Study: 83088
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin solution
Study: 131310
Drug: 0.025% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tretinoin solution
Study: 25459098
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal ring (CVR) - 15 mcg ethinyl estradiol/150 mcg etonogestrel
Study: 25459098
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (COC) - 20 mcg ethinyl estradiol/100 mcg levonorgestrel
Study: 17324745
Drug: bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (5 mg)
Study: 16492206
Drug: Pioglitazone 30-45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30-45 mg/day
Study: 16492206
Drug: Gliclazide 80-320
Normalized name: gliclazide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 80-320 mg/day
Study: 8355859
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg tid
Study: 8355859
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg tid
Study: 23053685
Drug: Scapular-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scapular-focused treatment
Study: 22166673
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with daily interruption
Study: 19092340
Drug: TAC-ST (Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-ST (Tacrolimus - Short-term Steroid)
Study: 12900683
Drug: L-arginine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine + CHO (10 g L-arginine with 70 g carbohydrate)
Study: 9109106
Drug: m-CPP administration
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP administration
Study: 29490012
Drug: Structured, moderate-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured, moderate-intensity physical activity (PA) program consisting of center-based (twice/week) and home-based (three to four times per week) aerobic, resistance, and flexibility training
Study: 26858193
Drug: Everolimus initiated
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus initiated at 4.5 mg/m2/day, titrated to blood trough levels of 5-15 ng/mL.
Study: 24453831
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (DD) of aspirin and clopidogrel (n = 58)
Study: 24453831
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) of aspirin and clopidogrel (n = 58)
Study: 24453831
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (DD) of aspirin and clopidogrel
Study: 18256968
Drug: Psychotherapy methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy methods (brief interventions and cognitive-behavioral therapy)
Study: 15870437
Drug: Dose-dense ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense ICE chemotherapy (4-week interval)
Study: 15870437
Drug: Standard ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ICE chemotherapy (2-week interval)
Study: 8694724
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% ketorolac tromethamine
Study: 8694724
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% diclofenac sodium
Study: 1723467
Drug: Nitrendipine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine, 20 mg b.i.d.
Study: 1723467
Drug: Nitrendipine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine, 20 mg once daily
Study: 31851556
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) in combination with intensive induction and consolidation therapy
Study: 21346613
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment (up to 12 weeks)
Study: 11506099
Drug: Metaraminol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaraminol infusion starting at 0.25 mg/min
Study: 11506099
Drug: Ephedrine infusion
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine infusion starting at 5 mg/min
Study: 28856661
Drug: Silk garments
Normalized name: SILK
DrugBank: Bombyx mori fiber (DB10609)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silk garments for the treatment of eczema
Study: 27271870
Drug: Massed mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massed mental practice (60 min of MP during a single daily session)
Study: 24385079
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (dose A: 3 injections of 2 U in 0.05 mL of normal saline per injection)
Study: 24385079
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (dose B: 3 injections of 4 U in 0.05 mL of normal saline per injection)
Study: 24385079
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (both doses)
Study: 10386821
Drug: T enanthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate (100 mg IM, weekly) + LNG 125 microg by mouth, daily
Study: 10386821
Drug: T enanthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate (100 mg IM, weekly) + LNG 250 microg by mouth, daily
Study: 10386821
Drug: T enanthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate (100 mg IM, weekly) + LNG 500 microg by mouth, daily
Study: 10386821
Drug: T enanthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate (100 mg IM, weekly) + Placebo LNG
Study: 1505563
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg b.i.d. and 20 mg b.i.d. combined
Study: 6360754
Drug: HBIG (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIG (0.5 ml at birth, three months, and six months)
Study: 6360754
Drug: HBIG (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIG (1.0 ml at birth only)
Study: 26313450
Drug: ranirestat 40
Normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranirestat 40 mg/day
Study: 26313450
Drug: ranirestat 80
Normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranirestat 80 mg/day
Study: 21420107
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with red light and skin contact
Study: 21420107
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with red light without skin contact
Study: 10642965
Drug: Daily membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily membrane sweeping (group II)
Study: 10642965
Drug: Daily dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily dinoprostone (Cervidil) vaginal inserts (group I)
Study: 9032861
Drug: Gamma Knife
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma Knife radiosurgery with marginal dose of 25-30 Gy
Study: 1505293
Drug: Famotidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (1 mg/kg/day)
Study: 6429876
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (20 mg) and ethinylestradiol (0.04 mg)
Study: 30035582
Drug: #Tamojunto intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: #Tamojunto intervention (12 weekly classes)
Study: 27128613
Drug: MF/F‐MDI (mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F‐MDI (mometasone furoate 800 µg and formoterol fumarate 20 µg)
Study: 27128613
Drug: MF‐DPI (mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF‐DPI (mometasone furoate 800 µg)
Study: 19617580
Drug: Nonspecific factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific factors (e.g., patient expectations, therapeutic alliances)
Study: 2338028
Drug: Non-lacquered tablet
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-lacquered tablet (M 250 mg, P 25 mg, S 500 mg)
Study: 2338028
Drug: Lacquered tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacquered tablets (M 125 mg, P 12.5 mg, S 250 mg)
Study: 28444456
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (3.0 g/day post-training)
Study: 19700947
Drug: Prazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (mean dose: 5.7 ± 0.9 mg/day)
Study: 19700947
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean dose: 5.6 ± 1.2 mg/day)
Study: 12163794
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation (1-4 mg x kg(‐1) x hr(‐1))
Study: 7772482
Drug: Inert gel
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert gel base
Study: 2185611
Drug: Computerized administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computerized administration of SMAST‐13
Study: 2185611
Drug: Paper-and-pencil administration
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil administration of SMAST‐13
Study: 2185611
Drug: Computerized administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computerized administration of CAGE
Study: 2185611
Drug: Paper-and-pencil administration
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil administration of CAGE
Study: 2185611
Drug: Computerized administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computerized administration of quantity-frequency scale
Study: 2185611
Drug: Paper-and-pencil administration
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil administration of quantity-frequency scale
Study: 378509
Drug: Ticrynafen (TCN)
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticrynafen (TCN) 125 mg daily
Study: 378509
Drug: Probenecid (PBC)
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid (PBC) 500 or 1,000 mg daily
Study: 27692638
Drug: Lorcaserin extended-release
Normalized name: lorcaserin hydrochloride Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin extended-release 20-mg once-daily
Study: 27692638
Drug: Lorcaserin extended-release
Normalized name: lorcaserin hydrochloride Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin extended-release under fed conditions
Study: 27692638
Drug: Lorcaserin extended-release
Normalized name: lorcaserin hydrochloride Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin extended-release under fasted conditions
Study: 27692638
Drug: Lorcaserin immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin immediate-release 10-mg BID
Study: 24488700
Drug: SSRIs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs treatment
Study: 25642918
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of neuroendocrine factors, clinical characteristics, and gene polymorphisms
Study: 23998714
Drug: CRT (Cardiac-resynchronization
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT (Cardiac-resynchronization therapy)
Study: 7541916
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin‐6 (IL‐6) at doses of 0, 1, 2.5, or 5 micrograms/kg/d subcutaneously on days 4 to 13
Study: 7541916
Drug: Granulocyte colony‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony‐stimulating factor (G‐CSF) at a dose of 5 micrograms/kg/d subcutaneously beginning on day 4 until a postnadir absolute neutrophil count of more than 10 x 10(9)/L
Study: 7541916
Drug: Ifosfamide 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 2,000 mg/m2 with mesna 1,600 mg/m2 intravenously on days 1, 2, and 3, carboplatin 350 mg/m2 intravenously on day 1 only, and etoposide 75 mg/m2 intravenously on days 1, 2, and 3
Study: 27064
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of propranolol